Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 214

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 214
---

to the “Yissum” company. The “Yissum” company coordinates the economic activities for the Company’s research services
under an exclusive license agreement signed on November 24, 2022 (refer also to Note 11).

“Yissum”
owns 2.2%, 6.6%, 6.6% and 5.82% of the Company’s share capital as of December 31, 2024, July 23, 2024, December 31, 2022, and 2023,
respectively.

NOTE 13 – SEGMENT REPORTING

ASC 280, “Segment
Reporting,” establishes standards for reporting information about operating segments. Operating segments are defined as components
of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker
(“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s business is comprised of one operating
segment.

The Company’s
CODM is its Chief Executive Officer (“CEO”), who reviews financial information presented on a consolidated basis.

The CODM uses
consolidated net loss to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key
operating decisions, such as the allocation of budget between Research and development and General and Administrative expenses. Segment
assets that are reviewed by the CODM is reported within the Consolidated Balance Sheet as consolidated total assets.

The table
below summarizes the significant expense categories regularly reviewed by the CODM for the period commencing July 24 through December
31, 2024, for the period commencing January 1, 2024 through July 23, 2024 and for the year ended December 31, 2023:

|                             |     | Successor 
 2024      | For the period commencing July 24, 
                            through 
                       December 31, |     | Predecessor 
 2024        | For the period commencing January 1, 
                              through 
                             July 23, |     | 2023 |   Year ended 
 December 31, |
|:----------------------------|:----|:----------|-----------------------------------:|:----|:------------|-------------------------------------:|:----|:-----|-------------:|
| Clinical developments       |     |           |                                171 |     |             |                                  354 |     |      |          490 |
| Payroll expenses            |     |           |